Skip to main content
Caplight Logo









Vivacta Biotechnology (Shanghai) Co., Ltd.

Vivacta Biotechnology (Shanghai) Co., Ltd.

Private
ShanghaiHealthcare & Life Scienceshttps://vivacta-bio.com/

Last Round

Series A

Apr 29, 2026

Total Funding Raised

$50M

Momentum

Top 5%

of companies Caplight tracks

Company Overview

Vivacta Biotechnology (Shanghai) Co., Ltd. is a biotechnology company developing in vivo CAR-T therapies for cancer and autoimmune diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

biopharmaceuticaldrug discoveryoncologyimmunologyCAR-T cell therapylipid nanoparticleLNPbiotechsmall moleculebiologic drugclinical pipelinedrug licensingmolecular engineeringpreclinical developmentautoimmune disease

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Vivacta Biotechnology (Shanghai) Co., Ltd. Comparables

Compare Vivacta Biotechnology (Shanghai) Co., Ltd. with similar companies based on industry and business-model similarity.

Vivacta Biotechnology (Shanghai) Co., Ltd. comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Grit Biotherapeutics
59%
Gilead Sciences
57%
CREATE Medicines
55%

Vivacta Biotechnology (Shanghai) Co., Ltd. Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series AApr 29, 2026

Vivacta Biotechnology (Shanghai) Co., Ltd. Investors

Notable investors and investment history

Vivacta Biotechnology (Shanghai) Co., Ltd. investors
InvestorRounds
Loyal Valley CapitalSeries A
Eisai InnovationSeries A
OrbiMedSeries A
Xiamen C&D Emerging Industry Equity InvestmentSeries A
Beijing Shunxi FundSeries A
Hankang CapitalSeries A
Qiming Venture PartnersSeries A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Apr 29, 2026

    $50M round led by Decheng Capital.

Vivacta Biotechnology (Shanghai) Co., Ltd. Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Vivacta Biotechnology (Shanghai) Co., Ltd. Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Vivacta Biotechnology (Shanghai) Co., Ltd.'s valuation, stock price, and market status.

Firmographic Details

HeadquartersShanghai
Year FoundedN/A
Last FundingApr 29, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?